Safety/risk assessment of electronic cigarettes

Dr Konstantinos Farsalinos

Researcher, Onassis Cardiac Surgery Center, Greece Researcher, University Hospital Gathuisberg, Belgium

E-cigarette facts

✓New in the market

Awareness and use growing exponentially

✓Used by millions, mostly of young age

Nicotine delivery, dealing with behavioral addiction

✓No tobacco, no combustion

Any regulation should be based on scientific evidence

Why do e-cigarettes exist?

- NRTs < 6% success rate (Moore et al., BMJ 2009)
- Oral medications < 20% success rate (Rigotti et al., Circulation 2010)
- Smoking the most important controllablereversible risk factor for disease
- ✓ Quit or die strategy (?)

Laboratory

- Chemical
- Toxicology

Clinical

- Pathophysiology (short-term)
- Epidemiology (long-term)



Therapeutic Advances in Drug Safety

Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review

Konstantinos E. Farsalinos and Riccardo Polosa

Review

1-20 DOI: 10.1177/ 2042098614524430 © The Author(s), 2014.

Ther Adv Drug Saf

Reprints and permissions: http://www.sagepub.co.uk/ journalsPermissions.nav

Compared to what?
Clean air?
Using nothing?

E-cigarettes should be marketed for smokers only
 It is a <u>substitute</u> for smoking
 Users would have been smokers if e-cigarettes did not exist

Comparison with smoking

- Comparison with other reduced-risk products
- Take into consider the pleasure factor-acceptability by users

Laboratory
 Chemical

Toxicology


Clinical

• Pathophysiology (short-term)

• Epidemiology (long-term)


- Nicotine IS NOT the reason for smoking-related disease
- Officially IS NOT a carcinogen (IARC)
- DOES NOT cause lung disease
- Has minimal effect in CVD

 Even in e-cigarettes, it is NOT nicotine but other chemicals that may be problematic



Daily nicotine intake from e-cigarettes similar or lower than smoking

Etter, Addiction 2014



Farsalinos et al., Sci Rep 2014

35

Nitrosamines are major carcinogens in tobacco cigarettes

Table 3.Levels of nitrosamines found in electronic and tobacco cigarettes. Prepared based on information from Laugesen [2009],Cahn and Siegel [2011] and Kim and Shin [2013].

Product	Total nitrosamines levels (ng)	Daily exposure (ng)	Ratio ⁴
Electronic cigarette (per ml)	13	52 ¹	1
Nicotine gum (per piece)	2	48 ²	0.92
Winston (per cigarette)	3365	50 475 ³	971
Newport (per cigarette)	3885	50 775 ³	976
Marlboro (per cigarette)	6260	93 900 ³	1806
Camel (per cigarette)	5191	77 865 ³	1497

¹Based on average daily use of 4ml liquid

²Based on maximum recommended consumption of 24 pieces per day

³Based on consumption of 15 cigarettes per day

⁴ Difference (number-fold) between electronic cigarette and all other products in daily exposure to nitrosamines

Farsalinos & Polosa, Ther Adv Drug Safety

OPEN access Freely available online

PLOS ONE

Metal and Silicate Particles Including Nanoparticles Are Present in Electronic Cigarette Cartomizer Fluid and Aerosol

Monique Williams¹, Amanda Villarreal¹, Krassimir Bozhilov², Sabrina Lin¹, Prue Talbot¹*

Table 1. Elemental abundance in EC aerosol and cigarettes and associated health effects.

Element	Aerosol µg/10 puffs	Smoke µg/cig (~10 puffs)	Health Effects
Sodium	4.18	1.3 [40]	Inhalation may cause lung irritation, shortness of breath bronchitis [41].
Boron	3.83		Inhalation exposure: acute respiratory and ocular irritation [42].
Silicon	2.24		Upper respiratory irritation, coughing, shortness of breath, bronchitis [43,44].
Calcium	1.03		Nose/throat irritation, coughing/wheezing [45].
Iron	0.52	0.042 [40]	Respiratory irritation, fume metal fever, siderosis, fibrosis [46].
Aluminum	0.394	0.22 [40]	Impaired lung function, asthma, and pulmonary fibrosis [47].
Potassium	0.292	70 [40]	May originate from silicate beads along with sodium, calcium, and magnesium.
Sulfur	0.221		Nose/throat/lung irritation, coughing, shortness of breath, and bronchitis [48].
Copper	0.203	0.19 [40]	Respiratory irritation, coughing, sneezing, thoracic pain, runny nose and vineyard sprayer's lung [49].
Magnesium	0.066	0.070 [40]	Metal fume fever, respiratory irritation, tightness in chest, difficulty breathing [50].
Zinc	0.058	0.12–1.21 [40] 11.9 [51]	Metal fume fever, impaired pulmonary function, chest pain, coughing, dyspnea, shortness of breath [52].
Tin	0.037		Inorganic tin: pneumoconiosis (stannosis) and inflammation [53].
Lead	0.017	0.017-0.98 [40] 0.072 [54] 0.14 [51]	Can damage nervous system and kidneys [55]. Is a CA, RT, and RDT [56].

Table 1. Elemental Impurities for Drug Products

Element	Oral Daily Dose PDE ^a (μg/day)	Parenteral Daily Dose PDE (µg/day)	Inhalational Daily Dose PDE (µg/day)
Cadmium	25	2.5	1.5
Lead	5	5	5
Inorganic arsenic ^b	1.5	1.5	1.5
Inorganic mercury ^b	15	1.5	1.5
Iridium	100	10	1.5
Osmium	100	10	1.5
Palladium	100	10	1.5
Platinum	100	10	1.5
Rhodium	100	10	1.5
Ruthenium	100	10	1.5
Chromium	c	c	25
Molybdenum	100	10	•10 (ERR 1-Oct-2012)
Nickel	500	50	1.5
Vanadium	100	10	30
Copper	1000	100	•100 (ERR 1-Feb-2013)

^a PDE = Permissible daily exposure based on a 50-kg person.

^b See Speciation section.

^c Not a safety concern.

US Pharmacopoeia, 2013




Figure 3. Toxic emissions score, adjusted for nicotine, for electronic cigarette and popular cigarette brands. (Reproduced with permission from Laugesen [2009]).

Farsalinos & Polosa, Ther Adv Drug Safety

Table 4 Comparison of toxins levels between conventional and electronic cigarettes

Toxic compound	Conventional cigarette (µg in mainstream smoke) ³⁵	Electronic cigarette (µg per 15 puffs)	Average ratio (conventional vs electronic cigarette)
Formaldehyde	1.6–52	0.20–5.61	9
Acetaldehyde	52–140	0.11–1.36	450
Acrolein	2.4–62	0.07-4.19	15
Toluene	8.3–70	0.02-0.63	120
NNN	0.005-0.19	0.00008-0.00043	380
NNK	0.012–0.11	0.00011-0.00283	40

Toxic substances do exist, but levels far lower compared to tobacco cigarettes


Goniewicz et al, Tob Control 2013

Passive vaping

Table 4 Concentrations (µg/m³) of selected compounds during the 8-m³ emission test chamber measurement of e-cigarette A and conventional cigarette using Tenax TA and DNPH

			E-cigarette			Conventional cigarette
Compounds	CAS	Participant blank	Liquid 1	Liquid 2	Liquid 3	
1,2-Propanediol	57-55-6	<1	1	<1	<1	112
1-Hydroxy-2-propanone	116-09-6	<1	<1	<1	<1	62
2,3-Butanedione	431-03-8	<1	<1	<1	<1	21
2,5-Dimethylfuran	625-86-5	<1	<1	<1	<1	5
2-Butanone (MEK)	78-93-3	<1	2	2	2	19
2-Furaldehyde	98-01-1	<1	<1	<1	<1	21
2-Methylfurane	534-22-5	<1	<1	<1	<1	19
3-Ethenyl-pyridine ^a	1121-55-7	<1	<1	<1	<1	24
Acetic acid	64-19-7	<1	11	13	14	68
Acetone	67-64-1	<1	17	18	25	64
Benzene	71-43-2	<1	<1	<1	<1	22
Isoprene	78-79-5	8	6	7	10	135
Limonene	5989-27-5	<1	<1	<1	<1	21
m,p-Xylene	1330-20-7	<1	<1	<1	<1	18
Phenol	108-95-2	<1	<1	<1	<1	15
Pyrrole	109-97-7	<1	<1	<1	<1	61
Toluene	108-88-3	<1	<1	<1	<1	44
Formaldehyde ^b	50-00-0	<1	8	11	16	86
Acetaldehyde ^b	75-07-0	<1	2	2	3	119
Propanal ^b	123-38-6	<0.2	<0.2	<0.2	<0.2	12

Schripp et al, Indoor Air 2013



Romagna, Farsalinos et al, SRNT Europe 2012

 ✓ In conclusion, chemical studies have found that exposure to toxic chemicals from ECs is by <u>far lower</u> compared with tobacco cigarettes.

 Besides comparing the levels of specific chemicals released from tobacco and ECs, it should be taken into consideration that the <u>vast majority</u> of the >4000 chemicals present in tobacco smoke are completely absent from ECs.

Not enough done

Flavors ?? Aldehydes ?? Ingredients or contaminants ?? Temperature – wattage ?? Particle size and nicotine delivery

Farsalinos & Polosa, Ther Adv Drug Safety

Laboratory

- Chemical
- Toxicology

Clinical


- Pathophysiology (short-term)
- Epidemiology (long-term)

- Studies on cells and animals
- Provide more valuable information in terms of effects of use
- Methodological issues
 - Protocol design
 - Material handling in the lab
 - Dry puff phenomenon undetected




		itions					
Extracts	100% ^a	50% ^b	25% °	12.5% d	6.25% ^e	3.125% ^f	P*
Tuscan ¹	94.5 ± 2.8	99.8 ± 5.7	104 ± 1.5	101.4 ± 4.1	100.7 ± 5.9	98.6 ± 3.8	0.216
Black fire ¹	$96.3\ \pm 9.9$	93.4 ± 2.5	94.4 ± 1.6	104.6 ± 2.9	95.3 ± 4.3	97 ± 3.2	0.159
Ozone ¹	90.7 ± 9.9	95.9 ± 9.1	96.2 ± 4.3	94.9 ± 6	96.7 ± 5.1	97 ± 4.9	0.879
Reggae night ¹	81.3 ± 5.1	90.3 ± 3.7	89.5 ± 4.2	89.7 ± 3.4	90.2 ± 5.7	91.6 ± 4.2	0.132
Vanilla	100 ± 2.4	98.5 ± 3.5	100.3 ± 2.0	100.1 ± 0.8	104.1 ± 3.1	98.3 ± 3.3	0.183
7foglie ¹	81.4 ± 2.9	87.5 ± 1.5	89.4 ± 4.0	87.1 ± 8.3	89.6 ± 12.1	93.2 ± 10.7	0.587
Max blend ¹	96.2 ± 6.0	97 ± 6.9	102.1 ± 7.4	111.8 ± 4.5	114.3 ± 1.7	115.5 ± 5.3	0.003
Virginia ¹	78.4 ± 14.4	86.1 ± 13.5	91.3 ± 15.6	96.4 ± 16.2	106.3 ± 9.7	104.4 ± 10.7	0.478
Perique black ¹	79.3 ± 1.5	89.8 ± 2.4	94.7 ± 1.2	95.3 ± 5.2	95.1 ± 2.4	93.9 ± 3.4	< 0.001
Layton blend ¹	101.1 ± 1.0	103.7 ± 0.8	102.7 ± 2.8	100.6 ± 2.1	103.4 ± 5.5	97.9 ± 4.2	0.295
Hypnotic ¹	93.8 ± 10.8	95.2 ± 14.0	106.2 ± 6.5	97.4 ± 5.1	100.6 ± 7.4	98.5 ± 3.9	0.579
Hazelnut	88.7 ± 1.4	90.1 ± 5.6	93.5 ± 6.7	91.5 ± 1.5	115.3 ± 8.0	117.8 ± 13.4	0.001
Shade ¹	83.6 ± 5.1	92.5 ± 3.9	94.6 ± 5.0	97.8 ± 5.9	101.5 ± 2.5	101.9 ± 1.3	0.002
$RY4^{1}$	88.4 ± 8.1	96.1 ± 3.7	98.7 ± 6.4	95.8 ± 7.4	98.9 ± 6.3	98.9 ± 5.9	0.378
Strawberry	85.8 ± 2.8	95.4 ± 2.3	97.5 ± 1.5	104.0 ± 6.2	99.6 ± 1.4	107.5 ± 1.2	< 0.001
Managua	79.1 ± 2.4	79.9 ± 3.3	79.1 ± 3.1	85.8 ± 2.0	86.4 ± 1.7	88.5 ± 3.5	0.002
Burley	102.2 ± 3.4	95.8 ± 2.9	97.6 ± 1.3	97.3 ± 3.4	106.2 ± 8.3	100.5 ± 6.2	0.171
Apple	95.2 ± 1.2	87.4 ± 2.7	100.8 ± 8.2	95.6 ± 3.9	101.8 ± 3.1	106.6 ± 15.6	0.106
Licorice	95.4 ± 3.9	93.9 ± 2.8	96.5 ± 2.6	98.5 ± 4.4	98.9 ± 2.0	99.6 ± 2.5	0.252
Chocolate	87.6 ± 2.2	89.6 ± 0.6	93.2 ± 1.3	93.4 ± 1.5	93.7 ± 1.9	98.9 ± 1.2	< 0.001
Coffee	51.0 ± 2.6	85.9 ± 11.8	92.0 ± 8.9	101.5 ± 3.1	112.2 ± 3.6	114.5 ± 1.1	< 0.001
CS	5.7 ± 0.7	9.4 ± 5.3	5.9 ± 0.9	72.8 ± 9.7	77.8 ± 1.8	89.1 ± 3.5	< 0.001

Komagna, Farsalinos et al, Inhal Toxicol 2013



Relative difference in viability between cigarette smoke and worst-performing vapor extract


Romagna, Farsalinos et al, Inhal Toxicol 2013



Behar et al, Toxicol in Vitro 2013

			Dilutions			
Samples-nicotine (mg/mL)	100% ^a	50% ^b	25%°	12.5% ^d	6.25%°	p *
Base-0	105.1 ± 1.2	103.5 ± 1.9	101.3 ± 4.2	100.7 ± 3.4	100.4 ± 2.3	0.251
Golden Margy-6	89.2 ± 0.2	93.0 ± 2.2	92.1 ± 1.3	95.3 ± 3.6	93.0 ± 6.3	0.361
RY69-6	98.9 ± 4.6	101.2 ± 5.4	96.0 ± 13.0	100.5 ± 2.7	100.2 ± 9.2	0.932
City-6	93.6 ± 2.5	89.4 ± 4.2	94.6 ± 2.3	93.3 ± 2.3	93.8 ± 2.8	0.282
Cinnamon Cookies-6	64.8 ± 2.5	100.8 ± 2.0	97.2 ± 2.9	99.3 ± 1.7	99.2 ± 3.8	<0.001
Golden Virginia-8	86.6 ± 1.8	89.1 ± 1.0	94.2 ± 3.0	95.5 ± 0.7	97.1 ± 1.4	<0.001
RY4-9	73.8 ± 3.7	106.6 ± 1.1	104.4 ± 1.9	103.6 ± 4.0	100.7 ± 0.8	<0.001
MaxBlend-9	104.4 ± 1.6	102.4 ± 2.0	102.4 ± 2.8	101.2 ± 7.6	102.7 ± 2.0	0.901
Americano-9	85.0 ± 2.0	98.3 ± 1.7	90.9 ± 4.4	94.7 ± 3.5	94.1 ± 5.9	0.017
American Tobacco-11	109.0 ± 1.6	106.8 ± 0.5	104.9 ± 1.0	101.3 ± 3.1	103.6 ± 2.5	0.007
Tribeca-12	110.8 ± 2.8	103.9 ± 5.5	106.6 ± 7.9	102.4 ± 5.1	101.7 ± 3.0	0.268
Green apple-12	106.6 ± 2.0	106.8 ± 2.0	105.2 ± 3.3	103.6 ± 4.5	99.2 ± 2.5	0.060
El Toro Cigarrillos-12(1) f	39.1 ± 1.2	52.5 ± 1.8	81.0 ± 2.0	92.6 ± 0.4	99.2 ± 1.0	<0.001
El Toro Cigarrillos-12(2) f	22.3 ± 4.0	66.9 ± 6.2	104.1 ± 5.8	109.9 ± 6.0	112.0 ± 8.8	<0.001
Silverberry-12	108.2 ± 8.5	107.2 ± 2.7	106.0 ± 1.7	103.2 ± 0.7	100.3 ± 2.0	0.200
Virginia-18	82.1 ± 0.8	95.8 ± 8.6	95.1 ± 3.0	90.6 ± 7.0	93.3 ± 8.5	0.136
Classic-18	95.0 ± 5.1	104.0 ± 9.1	101.1 ± 12.9	107.3 ± 8.3	89.7 ± 6.4	0.176
Tobacco echo-18	96.1 ± 5.0	96.4 ± 7.7	101.7 ± 3.1	102.7 ± 4.7	96.3 ± 7.3	0.479
Bebeka-18	75.7 ± 8.6	87.5 ± 2.2	90.8 ± 1.6	95.9 ± 1.9	99.0 ± 2.3	<0.001
El Toro Guevara-18 f	84.5 ± 3.0	91.0 ± 3.5	94.6 ± 1.3	98.8 ± 2.0	102.5 ± 1.7	<0.001
El Toro Puros-24 f	2.2 ± 0.6	7.4 ± 3.9	84.5 ± 6.5	115.3 ± 11.7	111.9 ± 7.4	<0.001
CS ²	3.9 ± 0.2	5.2 ± 0.8	3.1 ± 0.2	38.2 ± 0.6	76.9 ± 2.0	<0.001

Farsalinos et al, Int J Environm Res Public Health 2013



Untreated cells

E-cigarette vapor treated cells Cigarette smoke treated cells

Farsalinos et al, Int J Environm Res Public Health 2013

Are there really conflicting results ??

Farsalinos group

Experiments on vapor Use of refill liquids Using an e-cigarette device Using ISO 10993-5 protocol Tests on fibroblasts-heart cells

Talbot group

Experiments on liquids Possible use of concentrated flavors **No** use of an e-cigarette device Using in-house methodology Tests on nerve-stem cells-fibroblasts

Research should represent realistic use

- Laboratory
 - Chemical
 - Toxicology
- Clinical
 - Pathophysiology (short-term)Epidemiology (long-term)



Clinical studies

Lipoid pneumonia from inhalation of <u>oily</u> liquidsflavors (sold for food use)

Uneducated, irresponsible, dangerous producers (minority)

Business associations unable to control, regulate, define standards, expel members

No consultation with experts

Clinical studies

- Surveys show that dedicated vapers have significant benefits
- Randomized trials show small smoking cessation potential
- Not easy to assess the variability of devices and batteries
- Long-term studies CANNOT be performed now
- Are long-term studies needed for medicines approval?
- Imagine any product that needs 15 year clinical studies before being marketed → IMPOSSIBLE to happen

Acute studies

- Lung function: one study showed mild restriction, another one showed no adverse effects (Vardavas et al., Chest 2012, Flouris et al., Inhal Toxicol 2013).
- Cardiovascular function: no adverse effects on heart function, no adverse effects on oxygen delivery to the heart, no adverse effects on arterial stiffness (Farsalinos et al., ESC 2012, ESC 2013, ESC 2014)

Worldwide survey

Int. J. Environ. Res. Public Health 2014, 11, 4356-4373; doi:10.3390/ijerph110404356

Article

Characteristics, Perceived Side Effects and Benefits of Electronic Cigarette Use: A Worldwide Survey of More than 19,000 Consumers

Konstantinos E. Farsalinos ^{1,*}, Giorgio Romagna ², Dimitris Tsiapras ¹, Stamatis Kyrzopoulos ¹ and Vassilis Voudris ¹

19441 dedicated vapers evaluated

		Current	Former		
Changes	Total	smokers		Ctatistia	n volue
Changes	(n = 19,353)		smokers (n = 15.671)	Statistic	p value
		(n = 3682)	(n = 15,671)		
After initiating EC use, have you					
experienced any changes in:					
Physical status in general					
Worse	79 (0.4)	24 (0.7)	55 (0.4)		
No change	4769 (24.6)	1309 (35.6)	3460 (22.1)	$\chi^2 = 308.6$	< 0.001
Better	14,409 (74.5)	2316 (62.9)	12,093 (77.2)		
Smell					
Worse	29 (0.1)	12 (0.3)	17 (0.1)		
No change	2538 (13.1)	894 (24.3)	1644 (10.5)	$\chi^2 = 518.4$	<0.001
Better	16,722 (86.4)	2743 (74.5)	13,979 (89.2)		
Taste					
Worse	62 (0.3)	26 (0.7)	36 (0.2)		
No change	3359 (17.4)	1051 (28.5)		$\chi^2 = 431.6$	<0.001
Better	15,857 (81.9)			~	
Breathing					
Worse	137 (0.7)	40 (1 1)	97 (0.6)		
No change		784 (21.3)		$v^2 = 304.0$	< 0.001
Better	16,641 (86.0)			λ = 504.0	<0.001
	10,041 (80.0)	2024 (70.7)	15,617 (66.2)		
Appetite	210 (1.1)	56 (1.5)	162 (1.0)		
Worse	218 (1.1)		162 (1.0)	2	
No change	12,807 (66.2)		10,243 (65.49)	χ ² = 41.5	<0.001
Better	6216 (32.1)	1022 (27.8)	5194 (33.1)		

Table 5. Changes in physiologic functions after electronic cigarette use initiation.

Farsalinos et al, Int J Environm Res Public Health 2014



What is needed?

- Materials used in atomizers (wick, coil, plastics)
- Effects of high wattage
- New-generation devices-no tests
- Many vendors, many manufacturers, wrong criteria in production
- Vapers have not applied pressure for testing and research-wrong criteria in product selection

What is needed?

- No participation from the industry
- Lack of expertise
- No involvement of experts-none asks them, none pays them
- No consultation
- No testing, or wrong testing
- Big Tobacco is coming and will DOMINATE
- Regulators are forced to accept the Big Tobacco
- We need variability of products (competition) but also proof for benefit

Conclusions

- A public health revolution
- No doubt that they are less harmful by a big margin
- Need proof for benefit \rightarrow more research
- Need to remove harmful ingredients when avoidable-liquid and vapor analyses
- Products need improvement
- Better nicotine delivery
- Inefficient products will disappear
- Companies will disappear when irresponsible and do not provide proof of analyses

Grazie tanto per la sua attenzione